Meeting
2022 ASCO Annual Meeting
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
Authors
Natalia Lukashchuk
AstraZeneca, Cambridge, United Kingdom
Natalia Lukashchuk , Joshua Armenia , Luis Tobalina , Thomas Hedley Carr , Tsveta Milenkova , Ying L Liu , Richard T. Penson , Mark E. Robson , Elizabeth Harrington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02983799, NCT02282020, NCT02000622
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5559)
DOI
10.1200/JCO.2022.40.16_suppl.5559
Abstract #
5559
Poster Bd #
438
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?
First Author: Saeed Rafii
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2022 ASCO Annual Meeting
Breast cancer incidence in patients with BRCA-related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III clinical trials.
First Author: Michele Bartoletti